Sio Gene Therapies Inc. develops gene therapies for neurodegenerative diseases, working with companies like Oxford BioMedica and The University of Massachusetts Medical School to commercialize product candidates such as AXO-Lenti-PD and AXO-AAV-GM. Formerly known as Axovant Gene Therapies Ltd., the company changed its name in November 2020 and was founded in 2014 in New York.